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Abstract
Most differentiated cells convert glucose to pyruvate in the cytosol through glycolysis, followed by 
pyruvate oxidation in the mitochondria. These processes are linked by the Mitochondrial Pyruvate 
Carrier (MPC), which is required for efficient mitochondrial pyruvate uptake. In contrast, 
proliferative cells, including many cancer and stem cells, perform glycolysis robustly but limit 
fractional mitochondrial pyruvate oxidation. We sought to understand the role this transition from 
glycolysis to pyruvate oxidation plays in stem cell maintenance and differentiation. Loss of the 
MPC in Lgr5-EGFP positive stem cells, or treatment of intestinal organoids with an MPC 
inhibitor, increases proliferation and expands the stem cell compartment. Similarly, genetic 
deletion of the MPC in Drosophila intestinal stem cells also increases proliferation, whereas MPC 
overexpression suppresses stem cell proliferation. These data demonstrate that limiting 
mitochondrial pyruvate metabolism is necessary and sufficient to maintain the proliferation of 
intestinal stem cells.
Introduction
It was first observed almost 100 years ago that, unlike differentiated cells, cancer cells tend 
to avidly consume glucose, but not fully oxidize the pyruvate that is generated from 
glycolysis 1. This was originally proposed to be due to dysfunctional or absent mitochondria, 
but it has become increasingly clear that mitochondria remain functional and critical. 
Mitochondria are particularly important in proliferating cells because essential steps in the 
biosynthesis of amino acids, nucleotide and lipid occur therein 2–5. Most proliferating stem 
cell populations also exhibit a similar glycolytic metabolic program 6–9, which transitions to 
a program of mitochondrial carbohydrate oxidation during differentiation 10,11. The first 
distinct step in carbohydrate oxidation is import of pyruvate into the mitochondrial matrix, 
where it gains access to the pyruvate dehydrogenase complex (PDH) and enters the 
tricarboxylic acid (TCA) cycle as acetyl-CoA. We, and others, recently discovered the two 
proteins that assemble to form the Mitochondrial Pyruvate Carrier (MPC) 12,13. This 
complex is necessary and sufficient for mitochondrial pyruvate import in yeast, flies and 
mammals, and thereby serves as the junction between cytoplasmic glycolysis and 
mitochondrial oxidative phosphorylation. We previously showed that decreased expression 
and activity of the MPC underlies the glycolytic program in colon cancer cells in vitro and 
that forced re-expression of the MPC subunits increased carbohydrate oxidation and 
impaired the ability of these cells to form colonies in vitro and tumors in vivo 14. This 
impairment of tumorigenicity was coincident with a loss of key markers and phenotypes 
associated with stem cells. This prompted us to examine whether glycolytic non-transformed 
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stem cells might also exhibit low MPC expression and mitochondrial pyruvate oxidation, 
which must increase during differentiation.
Results
MPC expression is low in intestinal stem cells and increases upon differentiation.
As a model system, we have studied LGR5+ intestinal stem cells (ISCs), which reside near 
the base of the intestinal crypt and continuously proliferate. Their progeny differentiate and 
populate the intestinal epithelium, which is completely renewed approximately every 5 days 
15,16
. Using EGFP fluorescence from an Lgr5-EGFP-IRES-CreERT2 allele, we single-cell 
sorted intestinal crypt stem cells into low, medium and high LGR5-expressing populations 
(Supplemental Fig. 1a). As expected Lgr5 mRNA, as well as that of other markers of stem 
cells, correlated with Lgr5-EGFP expression, while Krt20 and other markers of 
differentiation anti-correlated with EGFP (Fig. 1a,b; Supplemental Table 1). The pattern of 
Mpc1 and Mpc2 expression resembled that of differentiation genes, exhibiting lower 
expression in the more stem-like cells that increased with differentiation. In vitro organoids 
maintained in stem cell or differentiation-promoting conditions displayed a similar pattern. 
When grown in basal medium containing EGF and Noggin, organoids exhibit a largely 
differentiated gene expression pattern, which is progressively more stem-like when R-
spondin 1 and Wnt3a are added to the medium (Fig. 1c,d; Supplemental Table 2). 
Expression of Mpc1 and, to a lesser extent, Mpc2 again correlate with the expression of 
differentiation genes. Both in vivo and in vitro, the expression of indicators of mitochondrial 
biogenesis like Tfam and Nrf1 was higher in more stem-like cell populations (Fig. 1a-d) 
suggesting that the decreased MPC expression is not due to a global suppression of 
mitochondrial gene expression. Similarly, immunohistochemical analysis of the proximal 
small intestine (jejunum) revealed that MPC1 was nearly absent from the base of the crypt, 
the site of LGR5+ ISCs, but strongly expressed through the upper crypt and villus, whereas 
VDAC, a marker of total mitochondrial mass, was more abundant at the base of the crypt 
relative to the remainder of the intestinal epithelium in both mouse and human (Fig. 1e). 
Similar anti-correlation of MPC1 and LGR5 expression was observed by 
immunofluorescence staining of small intestine (Fig. 1f). This pattern of MPC1 and VDAC 
expression was consistent throughout the murine small intestine (jejunum and ileum) and 
NRF1, TFAM, and PDK1 were also more abundant in the crypt cells in human intestine 
while the differentiation mark CK20 was less abundant17,18 (Supplemental Fig. 1b, c). 
Electron microscopy also showed high mitochondrial content in crypt stem cells, and 
isolated Lgr5-EGFP stem cells robustly stain with a dye dependent on mitochondrial 
membrane potential (Fig. 1g,h). These data are consistent with the hypothesis that crypt 
stem cells contain functional mitochondrial, but that they are geared toward biosynthetic 
activities or oxidation of fatty acids or other non-carbohydrate fuels.
Drosophila MPC regulates intestinal stem cell proliferation.
These observations led us to hypothesize that the MPC plays an active and direct role in 
regulating ISC proliferation. To begin to test this hypothesis, we examined the role of the 
MPC in the ISCs of the fruit fly Drosophila, which share key aspects of their biology with 
mammalian ISCs 19,20. Both MPC1 and MPC2 are expressed in all four cell types of the 
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intestine, with the lowest level of expression in the ISCs and the highest expression in the 
differentiated enteroendocrine cells 21,22. Confocal imaging of intestines dissected from 
dMPC1 mutants revealed that the epithelium exhibits multi-layering unlike the normal single 
cell layer seen in controls (Fig. 2a). This is a classic overgrowth phenotype that is associated 
with oncogene mutations in Drosophila 20. Accordingly, we used MARCM clonal analysis 
to determine if a specific loss of the MPC in ISCs leads to an increase in their proliferation 
23
. On average, newly-divided GFP-marked dMPC1 mutant clones are more than two-fold 
larger than control clones, which were generated in parallel using a wild-type chromosome, 
indicating that the MPC is required in the ISC lineage to suppress proliferation (Fig. 2b; 
Supplemental Table 7). Because GFP-marked clones could include cells that differentiate 
into mature enterocytes or enteroendocrine cells, we also conducted clonal analysis in the 
absence of Notch, thereby blocking ISC differentiation 24,25. Under these conditions, we 
again observed an approximately two-fold increase in the size of dMPC1 mutant ISC clones 
(Fig. 2c; Supplemental Table 7). To confirm and extend these results, we disrupted MPC 
function specifically in the ISCs by using the Dl-GAL4 driver in combination with UAS-
GFP, which facilitates stem cell identification. Once again, approximately two-fold more 
GFP-marked stem cells were observed relative to controls when either dMPC1 or dMPC2 
expression was disrupted by RNAi along with increased ISC proliferation as detected by 
staining for phosphorylated histone H3 (pHH3) (Fig. 2d). Similar results were obtained 
when RNAi was targeted to the E1 or E2 subunits of PDH to specifically disrupt the next 
step in mitochondrial pyruvate oxidation (Fig. 2d; Supplemental Fig. 2a; Supplemental Table 
7). Importantly, an opposite phenotype was seen when Ldh was reduced by RNAi in the 
ISCs or progenitor cells (Fig. 2e,f; Supplemental Fig. 2a; Supplemental Table 7). Ldh 
suppression is known to result in a significant increase in pyruvate levels, which can 
promote pyruvate oxidation 26. Taken together with our results with Pdh RNAi, these 
observations support the model that the MPC limits stem cell proliferation through 
promoting oxidative pyruvate metabolism in the mitochondria. It also appears to be 
sufficient as specific overexpression of MPC1 and MPC2 in ISCs or progenitors caused a 
reduction in stem cell proliferation, the opposite of the loss-of-function phenotype. This can 
be seen in either Pseudomonas-infected intestines (Fig. 2e; Supplemental Fig. 2a), which 
undergo rapid stem cell proliferation 27, or under basal conditions in aged animals (Fig. 2f). 
Consistent with this, MPC overexpression under basal conditions had no effects on intestinal 
morphology, while the intestines from infected flies displayed a fully penetrant size 
reduction, likely due to the inability of ISCs to maintain tissue homeostasis (Fig. 2g; 
Supplemental Fig. 2b, 7c). Taken together, our results demonstrate that mitochondrial 
pyruvate uptake and metabolism is both necessary and sufficient in a stem cell autonomous 
manner to regulate ISC proliferation and maintain intestinal homeostasis in Drosophila.
MPC deletion in the Lgr5-EGFP cells expands the intestinal stem cells compartment and 
increases proliferation.
To test whether loss of the mammalian MPC might have similar effects on ISC homeostasis, 
we generated mice carrying the Lgr5-EGFP-IRES-CreERT2 allele together with 
homozygous floxed alleles of Mpc1 (Supplemental Fig. 3a). Tamoxifen treatment resulted in 
a significant but incomplete (~30%) loss of MPC1 in the proximal small intestine at 30 days 
(Fig. 3a,f). Loss of MPC1 had no effect on body weight and caused no change in the 
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morphology or height of intestinal crypts or villi (Fig. 3a; Supplemental Fig. 3b,c,d). We 
also observed no change in Alcian blue staining, which marks goblet cells or perturbation in 
the mature enterocyte marker CK20 (Fig. 3a; Supplemental Fig. 3e). These animals 
exhibited, however, a significant increase in the number and zone size of actively 
proliferating cells in the crypt as measured both by BrdU incorporation and Ki67 staining 
(Fig. 3b,c; Supplemental Fig. 3f). In addition, Mpc1Lgr5-KO mice had an increased number 
of crypt stem cells as assessed by Olfm4, Lgr5, and LRIG1 expression as well as by 
expression of GFP from the Lgr5-EGFP allele (Fig. 3d,e; Supplemental Fig. 3g,h,i). 
Consistent with these data, we found that the zone of MPC1-deficiency increased over time 
post-Mpc1 deletion, suggesting positive selection for Mpc1 deleted cells (Fig. 3f). These 
data support our results in Drosophila and demonstrate that Mpc1Lgr5-KO crypts display 
increased cell cycling and ISC expansion.
In vitro loss of the MPC increases stem cell function and organoid formation.
A dramatic increase in organoid forming potential was observed after plating crypts isolated 
from Mpc1Lgr5-KO mice, supporting the conclusion that these animals have an enlarged 
population of proliferating ISCs (Fig. 4a; Supplemental Table 7). Similar results were seen 
when organoids were established from single Lgr5+ stem cells treated with tamoxifen in 
vitro to eliminate MPC1 (Fig. 4b; Supplemental Table 7), exhibiting more Lgr5-EGFP-
positive branches (Fig. 4c). When cells from these organoids were dissociated and sorted, 
Mpc1Lgr5-KO organoids maintained a higher fraction of GFP-positive cells (Fig. 4d; 
Supplemental Fig. 4a; Supplemental Table 7). When cells from these wild-type and 
Mpc1Lgr5-KO organoids were dissociated, but not sorted for EGFP, those from Mpc1Lgr5-KO 
organoids maintained their increased organoid forming ability (Fig. 4e) and were more likely 
to be Lgr5-EGFP positive (Fig. 4f). This increase in organoid formation of single 
Mpc1Lgr5-KO cells was maintained over extended passaging over two months (Supplemental 
Fig. 4b). Moreover, Mpc1Lgr5-KO organoids transferred to basal medium lacking the drugs 
that maintain stemness rapidly lost EGFP fluorescence, while Mpc1Lgr5-KO organoids 
retained significant EGFP expression surrounding the auto-fluorescent lumen (Fig. 4g).
In vitro loss of the MPC alters protein expression and metabolism.
To further define the molecular effects of MPC loss, we isolated wild-type and Mpc1Lgr5-KO 
organoid populations and subjected them to protein analysis. As expected, Mpc1-deleted 
organoids had an essentially complete loss of MPC1 protein, and a significant reduction in 
MPC2, which is dependent on MPC1 for its stability (Fig. 5a; Supplemental Fig. 4c, 7a,d) 
14,28–30
. Both the LGR5 and beta-catenin stem cell markers were elevated in Mpc1Lgr5-KO 
organoids (Fig. 5a; Supplemental Fig. 7a), consistent with effects on the mRNAs encoding 
stem and differentiation marks (Supplemental Fig. 4d, Supplemental Table 3). We also 
observed that histone acetylation, and specifically H3K27 and H3K4 acetylation marks, 
were decreased in Mpc1-deleted organoids (Fig. 5b; Supplemental Fig. 4e, 7b). As expected, 
Mpc1Lgr5-KO organoids exhibited a steady-state increase in pyruvate and a decrease in 
citrate, malate and alpha-ketoglutarate, consistent with a failure of cytoplasmic pyruvate to 
enter the mitochondrial TCA cycle (Fig. 5c; Supplemental Fig. 4f). Mpc1Lgr5-KO organoids 
also showed a significant impairment in flux of 13C-glucose into the TCA cycle as measured 
by M+0 loss and M+2 accrual in the citrate pool (Fig. 5d; Supplemental Table 7). Oxygen 
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consumption was also markedly impaired under both basal and FCCP-stimulated (maximal) 
conditions in both Mpc1Lgr5-KO organoids and wild-type organoids treated with UK-5099, 
which is a specific and efficacious MPC inhibitor 12,13,31 (Fig. 5e). No further decrease in 
oxygen consumption was observed when Mpc1Lgr5-KO organoids were treated with the 
inhibitor. This led us to explore whether fatty acid oxidation might be increased to 
compensate for loss of Mpc1-dependent carbohydrate oxidation. In fact, we found that 
etomoxir-sensitive respiration (i.e. fatty acid oxidation) was profoundly increased by either 
inhibition or genetic deletion of MPC function (Fig. 5f).
In vitro inhibition of MPC activity increases organoid formation.
In addition to genetically MPC-deficient organoids, we next utilized the MPC inhibitor 
UK-5099 to examine the effects of acute MPC loss. Similar to Mpc1Lgr5-KO organoids, we 
found that treatment of crypt-derived organoids with UK-5099 led to enhanced maintenance 
of EGFP expression in the epithelial lining (Fig. 6a) and a larger number of crypt-like 
branches per organoid, indicative of increased stem cell activity (Fig. 6b; Supplemental 
Table 7). We also observed that UK-5099 treatment caused an ~4-fold increase in the 
efficiency of organoid formation from proximal small intestine (Fig. 6c; Supplemental Table 
7). When treated organoids were dissociated and assessed by flow, UK-5099 treatment 
significantly increased the percentage of GFP positive cells (Fig. 6d; Supplemental Table 7). 
MPC inhibition enhanced organoid formation from all regions of the small intestine and 
from the colon to a degree similar to that of the canonical organoid maintaining condition 
containing valproic acid and CHIR99021 (Supplemental Fig. 5a). We also observed that 
human colon organoid colony formation and growth was promoted by UK-5099 treatment 
(Fig. 6e; Supplemental Table 7).
Interestingly, organoids could be maintained for at least one year of continuous UK-5099 
treatment and they continued to display an increase in crypt domains per organoid (Fig. 6f). 
The addition of UK-5099 also improved passaging efficiency of early crypts (Supplemental 
Fig. 5b). When organoids were transferred to differentiation conditions, treatment with 
UK-5099 resulted in maintenance of Lgr5-EGFP expression in the crypt domains (Fig. 6g). 
Similarly, when removing stem cell maintaining factors and allowing passive differentiation, 
UK-5099 delayed the emergence of highly autofluorescent organoid lumens suggesting 
fewer or lower activity of differentiated secretory cells (Supplemental Fig. 5c). We also 
examined the effect of MPC inhibition in comparison and combination with the HDAC 
inhibitor valproic acid and/or the GSK-3beta inhibitor CHIR99021, both of which promote 
stem cell maintenance independent of the Paneth cell niche 32. UK-5099 and valproic acid 
caused a similar increase in organoid formation from crypts relative to controls, and resulted 
in a similar additive effect when combined with CHIR99021 (Fig. 6h; Supplemental Table 7) 
with each drug being used at its optimal concentration (Supplemental Fig. 5d). The 
GSK-3beta inhibitor had stronger effects than either of the other two drugs alone and was 
also additive with all other combinations. We conclude that MPC inhibition has profound 
effects on stem cell maintenance that are at least partially mechanistically distinct from those 
caused by HDAC or GSK-3beta inhibition. Given the previous suggestion that valproic acid 
might inhibit the MPC 33,34, we examined 13C-glucose flux with and without valproic acid 
and found that valproic acid had no effect on the kinetics of citrate labeling demonstrating 
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that at the concentrations used, this drug does not inhibit MPC activity (Supplemental Fig. 
6a).
These observations of enhanced stem cell function and previously described metabolic 
effects (Fig. 5d,e,f) of UK-5099 treatment were accompanied by changes in the expression 
of molecular markers of stemness. UK-5099 treatment in mixed organoid populations led to 
a robust increase in several stem cell markers, including Lgr5, Ascl2, Cd44 and Myc, along 
with a substantial decrease in the abundance of the Krt20, Villin1, Chga and Fabp2 
differentiation markers (Fig. 6i, j, Supplemental Table 4). These data demonstrate that loss 
of mitochondrial pyruvate import leads to enhanced maintenance of molecular and 
functional markers of ISCs (and decreased markers of differentiation) to a degree similar to 
well-described stem cell maintaining agents.
Finally, we performed the converse of prior experiments and tested the hypothesis that 
forced expression of Mpc1 and Mpc2 in LGR5+ ISCs causes a loss of stemness. Indeed, 
using a previously validated system for overexpression 14, we found that those cells 
expressing exogenous Mpc1 and Mpc2, which are both required for MPC function, were 
much less likely to maintain Lgr5 expression, as indicated by EGFP fluorescence (Fig. 6k; 
Supplemental Fig. 6b; Supplemental Table 7). This is consistent with work suggesting that 
stimulating glucose oxidation with the small molecule dichloroacetate (DCA) or by 
substitution of glucose with galactose promotes differentiation 10.
Discussion
Our studies in Drosophila, intestinal organoids, and mice provide strong evidence that the 
MPC is necessary and sufficient in a cell autonomous manner to suppress stem cell 
proliferation. Consistent with this, we have demonstrated that ISCs maintain low expression 
of the subunits that comprise the MPC, which enforces a mode of carbohydrate metabolism 
wherein glucose is metabolized in the cytosol to pyruvate and other biosynthetic 
intermediates. This glycolytic metabolic program appears to be sufficient to drive robust and 
continuous stem cell proliferation 35. We also observed high mitochondrial content in ISCs, 
which must be geared primarily toward biosynthetic functions and/or oxidation of other 
substrates like fatty acids. Increased fatty acids, the metabolism of which is enhanced in 
MPC-deficient and MPC-inhibited organoids, have been shown to promote ISC expansion 
and proliferation via enhanced beta-Catenin signaling and increasing tumor initiating 
capacity 36. MPC expression increases upon differentiation, consistent with the shift in 
demand from macromolecule biosynthesis to ATP production in support of post-mitotic 
differentiated cell function. A similar switch in MPC expression can be seen upon 
differentiation of embryonic stem cells, hematopoietic stem cells, and trophoblast stem cells 
37–41
. Conversely, MPC expression is reduced upon reprogramming fibroblasts to iPSCs 
42–45
. This suggests that the effects of altering pyruvate flux that we observe herein might 
not be restricted to ISCs, but instead be representative of similar effects on multiple stem cell 
populations (see also accompanying manuscript on hair follicle stem cells). Interestingly, 
Myc is known to drive a metabolic program that is similar to that observed upon MPC loss, 
characterized by increased glycolysis and reliance on glutamine and fatty acid oxidation 
with reduced glucose oxidation 46–48. This suggests that Myc may play a role in repressing 
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the MPC in stem cells, possibly acting downstream of Wnt/beta-Catenin signaling 49. 
Consistent with this, Myc and its repressive co-factors localize to the Mpc1 promoter and 
Myc expression is strongly anti-correlated with Mpc1 expression (Supplemental Fig. 6c) 
14,50–53
.
Taken together, our studies demonstrate that changes in the MPC and mitochondrial 
pyruvate metabolism are required to properly orchestrate the proliferation and homeostasis 
of intestinal stem cells. Importantly, this metabolic program—mediated at least partially by 
the MPC—appears to be instructive for, rather than a downstream consequence of, cell fate. 
Future work will define the extent to which the results presented herein relate to those 
showing that diet quality and quantity can modulate ISC behavior. Is ISC metabolism used 
as a signal for increased or decreased demand for intestinal epithelium? Perhaps of most 
importance will be to define the mechanisms whereby altered partitioning of pyruvate 
metabolism affects stem cell proliferation and fate. We speculate that the robust changes in 
fatty acid oxidation and histone acetylation, likely downstream of altered metabolite 
utilization for acetyl-CoA production, that we observed play an important role 36,54–56. 
While the mechanisms are not as yet defined, these studies establish a paradigm wherein 
mitochondrial metabolism does not merely provide a permissive context for proliferation or 
differentiation, but rather plays a direct and instructive role in controlling stem cell fate.
Materials and Methods
Mice.
Heterozygous Lgr5-EGFP-IRES-CreERT2 mice were obtained from Jackson Labs 1. MPC1 
fl/fl mice were generated as previously described 2. Control animals consisted of Lgr5-
EGFP-IRES-CreERT2 × MPC1 wt/wt or MPC1 fl/fl mice negative for Lgr5-EGFP-IRES-
CreERT2. For in vivo knockout 6- to 8-week-old mice were injected intraperitoneally with 
100ul of 20mg/ml tamoxifen (Sigma Aldrich T5648) dissolved in peanut oil (Sigma Aldrich 
P2144) for three successive days and sacrificed 8, 30, or 160 days later. BrdU (Invitrogen 
b23151) was dissolved in PBS to 10mg/ml and 100uL was injected intraperitoneally 4 hours 
before sacrifice to label dividing cells. Injections were carried out in the morning (between 
7am and 11am) and tissue was collected 4 hours later +/− 10 minutes from the time of 
injection. A 2cm section was used for crypt dissociation and organoid formation as 
described below. The remainder of the small intestine was divided and fixed in buffered 10% 
formalin (Fisher Scientific 23–245-685) as previously described 3 for 48 hours, transferred 
to 70% ethanol and paraffin embedded for sectioning and staining. No formal randomization 
was performed for animal studies, animals were used as they came available, paired with 
littermate controls where possible, there was no preference for male or female animals, both 
genders were included in each analysis. All IACUC guidelines were followed and protocol 
submitted for animal experiments carried out in this study to the University of Utah 
Institutional Animal Care and Use Committee.
Drosophila Stocks.
Drosophila stocks were maintained on standard food containing 3% sucrose, 6% glucose, 
8% yeast, and 1% agar in a 25°C incubator. For dMPC1 genetic studies, control flies were 
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homozygous for a precise excision of the P(XP)CG14290[d00809] P-element insertion, and 
mutant flies were transheterozygous for the two deletion alleles, dMPC11 and dMPC12, as 
described {Bricker, 2012 #9}. Dl-GAL4 (a gift from B. Edgar) was used to target RNAi to 
the ISCs and esg-GAL4 (a gift from B. Edgar) was used to target RNAi to the ISCs and EBs. 
RNAi transgenic stocks are as follows: UAS-dMPC1 RNAi and UAS-dMPC2-RNAi 
{Bricker, 2012 #9}, UAS-PDH-E1 (VDRC101856), UAS-PDH-E2 (VDRC 102893), and 
UAS-Notch-RNAi (a gift from C. Micchelli). Temperature-sensitive Tub-GAL80ts was 
utilized to restrict RNAi to adults. For temperature shift experiments, animals were raised at 
18°C and 4–5 day adults were transferred to 29°C for days after which intestines were 
dissected for analysis. Pseudomonas infections were performed as described 4. The 
Pseudomonas strain was a gift from B. Edgar. Overexpression of the MPC was achieved by 
inserting the open reading frames for dMPC1 and dMPC2 downstream from the UAS 
promoter in the pUAST-attB vector, with the coding sequence for the P2A peptide joining 
the two MPC coding regions 5. This was inserted into the attP40 site on the second 
chromosome using standard methods, and expression was achieved using GAL4 drivers 
specific to the ISCs or progenitor cells. All Drosophila studies were done following standard 
ethical guidelines for working with this organism. As is standard in studies of Drosophila 
intestinal stem cells, all experiments were performed in females, which have a higher rate of 
basal stem cell proliferation than males. Experiments were conducted in adults aged four 
days to three weeks after eclosion.
Mosaic analysis.
The MARCM system was used to generate wild-type and dMPC1 mutant lineages as 
previously described 6. Four to five day old adult female flies of the following genotypes 
were subjected to two 38°C heat pulses for 30–40 minutes: y, w, hs-FLP, UAS-GFP / w; +; 
Tub-GAL4, FRT82B, Tub-Gal80 / FRT82B (control), y, w, hs-FLP, UAS-GFP / w; +; Tub-
GAL4, FRT82B, Tub-Gal80 / FRT82B dMPC11 (mutant). Clones were analyzed three 
weeks after induction. The number of nuclei in GFP-expressing clones were used for 
quantification. For the dMPC1 MARCM studies in the presence of Notch RNAi, intestines 
were analyzed five days after clone induction. Intestines were stained with antibodies to 
detect GFP and Prospero, with DAPI to mark nuclei. Animals of the following genotype 
were used: y, w, hs-FLP, UAS-GFP / w; UAS-Notch-RNAi; Tub-GAL4, FRT82B, Tub-
GAL80 / FRT82B (control, Notch RNAi only), y, w, hs-FLP,UAS-GFP / w; UAS-Notch-
RNAi; Tub-GAL4, FRT82B, Tub-GAL80 / FRT82B dMPC11 (Notch RNAi and dMPC1 
mutant clones). Only clones that were negative for EEs (Prospero negative) and ECs (larger 
nuclei) were included in the analysis.
Histology and immunostaining.
Adult flies were dissected in 1×PBS and the gastrointestinal tract was fixed in 4% 
formaldehyde (Polysciences Inc, EM grade) overnight at 4°C. Tissues were washed four 
times with 0.1% Triton, 1×PBS (PBST) and incubated with PBST and primary antibodies 
overnight, washed again, and then incubated for 3–4 hours with secondary antibodies in 
PBST. Samples were mounted using Vectashield (Vector, USA) with DAPI. Antibody 
information is found in Supplemental Table 5. Images were acquired using an Olympus 
FV1000 confocal microscope and assembled into Z stack projections for the figures. For the 
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RNAi experiments, GFP-positive cells were quantified per 40x frame in the mid-R2 region 
of the intestine. For the number of dividing cells, the average number of PHH3-positive cells 
for the entire midgut was reported.
Crypt and single-cell isolation.
Small intestinal crypts and single GFP positive cells were isolated as previously described 7. 
The entire small intestine was harvested, opened longitudinally and washed with PBS. 
Mucus and villi were scraped and discarded using a thin glass coverslip and tissue was cut 
into small (approximately 2cm) sections. These were washed again in PBS and incubated in 
2.5 mM EDTA diluted in PBS for 1 hour with gentle agitation at 4 degree C. Crypts were 
liberated and collected by centrifugation (400g for 5 minutes at 4 degree C) followed by 
washing with PBS to remove EDTA. Crypts in PBS were passed through a 70-um cell 
strainer and centrifuged as before. This pellet was resuspended in 50% culture media 
(described below) and 50% Corning Growth Factor Reduced matrigel (Fisher Scientific 
#356231) for culture or dissociated for single cells. Single cell isolation was carried out as 
described previously 8 by resuspending crypts in TrypLE Express (Invitrogen #1260413) 
with DNase I (Gold Biotechnology #D-300–1) for 10 minutes at 37 degree C. Dissociated 
cells were washed in culture media without growth factors, centrifuged at 700g, resuspended 
and passed through a 35-um strainer (Fisher Scientific #08–771-23) and analyzed by FACS. 
Neagtive staining was carried out with DAPI and single live cells were collected, pelleted, 
and snap frozen for analysis or resuspended for culture.
Culture of crypts and single cells.
Crypts or single cells were maintained as previously described 7 with minimal modification. 
For regional specific assays of organoid formation the intestine was divided up as follows: 
the duodenum was classified as the first 4–5 cm, jejunum was classified as the proximal half, 
and ileum the distal half. The entire colon, excluding the ceacum and rectum were pooled 
and crypts isolated. Media consisted of advanced DMEM/F12 (Invitrogen #12634028) 
media prepared with HEPES (Invitrogen #15630–080), Glutamax (Invitrogen #35050061), 
and Penicillin-Streptomycin (Invitrogen #15140122) with N-2 supplement (Invitrogen 
#17502048), B27 serum free supplement (Invitrogen #17504044) N-Acetyl-L-cysteine (1 
mM) containing all growth factors (Wnt3A to final concentration 2.5ng/ml: Peprotech #315–
20, Noggin to final concentration 100ng/ml: Peprotech #250–38, EGF to final concentration 
50ng/ml: Gold Biotechnology #1350–04-500, mRSPO1-Fc conditioned media from 293T 
cells provided by Calvin Kuo at Stanford University as previously described 9) and 50% 
matrigel (Fisher Scientific #356321). Crypts were resuspended in media and matrigel were 
spotted in the center of wells in a 48-well plate and allowed to polymerize at 37 degree C 
prior to overlaying with media. Inhibitors CHIR99021 (3 uM, R & D Systems #4423), 
Valproic acid (1 mM made fresh each day, R & D Systems #28–151-100), and UK-5099 (10 
uM, R & D Systems #4186) used to compare organoid formation from crypts were added to 
the crypt matrigel mixture as well as to the media overlay and changed every 2–3 days. 
These drug concentrations were identified as standard from previous studies (CHIR99021: 3 
uM, Valproic Acid: 1 mM, and UK-5099 10uM) but were titrated for efficacy at dosaged of 
0.5x, 1.0x, 3.0x, and 9.0x. Total organoid number as well as number of crypt domains per 
organoid were counted after 9 days. For single cells CHIR99021 and Valproic acid were 
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added to maintain Lgr5 stem cells as previously described 10 along with Rho Kinase 
inhibitor Y-27613 (10 uM Fisher Scientific #125410), Jagged-1 (1 uM AnaSpec, Inc 
#AS-61298).
Organoid knockout.
Single Lgr5-EGFP positive cells from MPC1 fl/fl × Lgr5-EGFP-IRES-CreERT2 were sorted 
and plated as above. Control genetically matched sampled received DMSO and genetic 
recombination was induced using (Z)-4-Hydroxytamoxifen (200nM, Fisher Scientific #34–
1210). Organoids grown from these were re-sorted for live EGFP positive cells and plated as 
above or collected for mRNA analysis. Prior to use of knockout organoid culture in further 
experiments, loss of MPC1 was verified by western blot where we also looked for a 
significant destabilization of MPC2. If we could still detect MPC1 protein, cultures were 
retreated with (Z)-4-Hydroxytamoxifen and purified by flow cytometry. In addition, we 
routinely assessed MPC1 when blotting for other targets to ensure the knockout was stable 
and no wild-type escaper cells repopulated the culture.
Secondary organoids.
Organoids were passaged to single cells as above. Cell viability was determined by 
exclusion of 0.2% Trypan Blue (Sigma Aldrich) and both cell number and viability counted 
using the Cellometer Auto T4 (Nexcelom). Based on live cell passaged, organoid formation 
and EGFP positivity was measured after 7–9 days once mature organoids had formed.
Organoid differentiation.
Organoids grown for differentiation were passaged to single cells and allowed to establish 
for 6–8 days in standard media then transferred to media lacking Wnt3A and RSPO1 
conditioned media (EN), Wnt3A (ENR), or media with 90ng/ml Wnt3A (ENR +Wnt). 
Organoids were maintained in this media for 48 hours with fresh media added after 24 
hours. To promote robust differentiation IWP-2 (2 uM Fisher Scientific #35–331-0) and 
DAPT (10 uM Fisher Scientific #26–341-0) were added to organoid media along with 
vehicle (DMSO) or UK-5099 (20 uM). Images were taken of live organoids to assess the 
loss of GFP signal. For passive differentiation, crypts were plated identically and allowed to 
form in wENR with CHIR and Valproic Acid. Media was then changed to basal media 
(wENR) treated with vehicle (DMSO) or UK-5099 (10 uM) and the emergence of 
hyperintense autofluorescent organoid lumens were observed and counted.
MPC Overexpression.
Viral infection of Lgr5 stem cells was carried out as previously described with modifications 
11
. Organoids were dissociated to single cells as described above with TrypLE and DNase 
followed by resuspension, filtering, and pelleting. This cell pellet was then resuspended in 
2x wENR that contained nicotinamide (10 mM), Y-27613 (10 uM), polybrene (10 ug/mL), 
and CHIR-99021 (3 uM). This cell suspension was added 1:1 with concentrated virus. The 
cell:virus mixture was incubated for 10 minutes at 37 degree, spun for 30 minutes at 200 × g 
at room temp, resuspended and plated into 48 well plates and incubated in a tissue culture 
incubator for 4 hours. After infection cells were collected from wells, centrifuged at 700 × g 
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for 10 minutes, washed and resuspended in fresh cold media. This was mixed with matrigel 
as described above and spotted for organoid growth. Lentivirus was produced as previously 
described 12. hMPC1 was subcloned into LeGO-iG2 from Addgene #27341 with GFP 
substituted for iRFP713 from Addgene #45468. hMPC2 was subcloned into LeGO-iC2 from 
Addgene #27345 (plasmid without MPC2 also used as empty vector control). Lentiviral 
packaging and expression vectors were transfected into 293T with Lipofectamine 2000 
(Invitrogen #11668019) to begin viral production. Supernatant was collected and pooled 
every 24 hours from 24–96hr. This was then spun at 1500 × g for 10 minutes to remove cell 
debris, passed through a 0.45 um filter, and centrifuged in ~30 mL aliquots overnight at 4 
degree at 14,000 × g to concentrate viral particles. This was then resuspended in ~ 500 uL 
HBSS and used for infection or aliquots and frozen at −80 degrees. Organoids from single 
cell infection were then allowed to form and imaged 6–8 days later for analysis.
Immunohistochemistry.
All tissue processing, staining, and analysis was done in a blinded manner. Paraffin sections 
(3–4 um for IHC, 7 um for ISH) were cut on positively charged slides (BBC), placed at 60 
degrees C for 30 minutes, and placed on automated slide stained (BenchMark, Discovery, 
Ventana Medical Systems) for processing. Slides were de-paraffinized with EZ prep 
solution, pre-treated with Cell Conditioner 1, pH 8.5, and stained with primary antibody for 
1 hour at 37 degrees C (Supplemental Table 5). Secondary antibody (rabbit 1:100 for 
VDAC1 and MPC1, rat 1:100 for BrdU) was applied and detection performed using IView 
DAB detection kit followed by hematoxylin counterstaining. Slides were scanned using an 
automated slide scanner (Zeiss Axio Scan.Z1). For analysis of Olfm4 and Lgr5 staining, 
images of swiss rolled proximal small intestine were used. Areas with a high density of 
crypts in cross section that were continuous with villi were used for counting number of 
stained cells. Multiple crypts from at least 3 different areas were counted and the average 
cell number was calculated per mouse. At least 9 control and 9 knockout animals were used 
and images were unused only if staining did not work or tissue orientation in cross section 
was inadequate for counting. For histological analysis all small intestinal tissue was 
processed, stained, and imaged blinded. Animals were excluded from analysis if tissue 
orientation, staining, or acquisition failed and precluded analysis and for no other reason. 
For analysis, images of the proximal small intestine were selected that contained areas with 
crypts in cross-section continuous with villi. 3 separate areas and a minimum of 10 total 
crypts were analyzed and averaged to give a value for that animal used for statistics. IRB for 
histology of human intestine: U of UT IRB 91019.
Immunofluorescence staining of mouse small intestine.
Tissue for immunofluorescence was prepared as follows: the jejunum from LGR5 Cre+ mice 
was extracted and fixed at room temp in 4% PFA × 2.5h. This was followed by washing in 
PBS and equilibrating in OCT on ice then transferred to a chilled mold that was frozen on 
dry ice and stored at −80˚C. From this block 10um sections were cut and transferred to 
slides, which were cured for 30 minutes at room temp in the dark. Slides were then soaked 
to wash OCT by placing horizontally in a humid box at 37˚C OCT 2× 5 min. with PBS+Ca
+Mg. Sections were blocked/permeablized by treating for 1 hour in humid dark box in 
1×PBS+Ca+Mg, 0.1% Saponin, 10% Donkey Serum, 3% BSA. For staining: anti-MPC1 
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sigma cat #HPA045119 in 1×PBS + 10% Nml Donkey Serum,+3% BSA – no Saponin at 
1:100, incubated in the dark overnight at 4˚C. The next morning, slides were washed 2 times 
with PBS for 2 minutes each. Secondary antibody (1:100 (10μg/ml Donkey anti-Rabbit IgG 
Alexa 594 conjugate) +5μg/ml DAPI in 1 × PBS +3% BSA) was incubated at room temp for 
3 hours. Slides were then washed twice with PBS as above and mounted using 100mg/ml 
PVP mounting medium.(Tris buffer +0.02% Azide,+5% DABCO,+100mg/ml 
Polyvinylpyrrolidone+ 1/25 volume glycerol) and cured for 2 hours at room temp.
Human colon crypt isolation and growth.
Human colon biopsy samples for organoid cultures were collected under IRB 00051140, 
Molecular markers of sporadic hyperplastic colon polyps. Patients with a history of 
inflammatory bowel disease or patients with a personal or family history of familial colon 
cancer were excluded from the study. Briefly, study patients underwent screening 
colonoscopy as part of their regular clinical care. Participants scheduled for colonoscopy 
were not recruited for the study alone. Informed consent was obtained prior to any sedation. 
The study was approved by the IRB at the University of Utah and VA medical center. All 
samples were labeled with code numbers to protect confidentiality. All procedures were 
clinically indicated and recommended by the patients’ physician or consultant. As per US 
preventative services task force (USPSTF), colon cancer screening is recommended for 
subjects who are 50 years and older for detection and management of colon polyps and 
colon cancer.
Removing colon polyps and obtaining colonic tissue is a standard procedure during 
colonoscopy. The biopsy forceps used to obtain colon biopsies are 2 to 3 mm in diameter. 
Endoscopic biopsies are commonly taken as part of regular clinical care to diagnose 
problems and evaluate suspicious tissues. The risks associated with this are minor; patients 
do not feel the biopsies because the colon does not have pain receptors (just stretch 
receptors), and bleeding is self-limited. In all situations, minimizing any potential risk to the 
participants was a priority. If in the clinical judgment of the physician, biopsies should not 
be taken, they are not. In addition, if taking biopsies will make the endoscopic procedure too 
long, they will not be taken.
Crypt imaging.
Intestinal crypts were isolated as above and transferred to basal media lacking growth 
factors. Mitotracker Red CMXRos (Invitrogen #M7512) was prepared according to 
manufacturers instructions and added to suspended crypts in media to a final concentration 
of 50 nM and incubated at 37 degree C for 20 minutes.
Organoid imaging.
Live organoids were imaged on the Axio Observer Z1 imaging system (Carl Zeiss) fitted 
with a heated humidity controlled stage (LiveCell 05–11-0032 Rev B) and analyzed using 
Zen 2 software (Carl Zeiss). Laser intensity was kept constant when making comparisons of 
organoids and adjustments for brightness and contrast were made to the entire image equally 
across groups being compared.
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In situ hybridization.—For detection of Lgr5 and Olfm4 mRNA, we designed riboprobes 
targeting the coding sequence to 3’UTR region of these genes (Supplemental Table 5). 
Targeted probe region DNA were amplified using standard PCR, with the amplicon length of 
about 500 bp. These DNA amplicons were used to generate DIG-labeled riboprobes using 
T7 RNA polymerase. For staining, Formalin fixed paraffin embedded tissue sections were 
deparaffinized with Citrisolv, washed in 100% ethanol, and air dried. Slides were blocked 
with Boeringer Blocking Reagent (Roche) and yeast tRNA at 68°C for 1 hour. 0.5 ng/mL 
probes were hybridized to sections at 68°C overnight. After washing, sections were again 
blocked with Boeringer Blocking Reagent and 10% sheep serum at room temperature for 1 
hour. Alkaline phosphatase labeled sheep anti-DIG antibody (Roche) was incubated with 
sections at 1:2000 dilution at 4°C overnight. After washing, positive signals were developed 
using NBT/BCIP substrate (Thermo). Slides were then fixed in 10% neutral buffered 
formalin and mounted with aqueous mounting medium.
RNA Extraction and Analysis.
Lgr5-GFP sorted cells were directly lysed in buffer RLT (Qiagen # 79216) containing 2-
mercaptoethanol (Sigma Aldrich #M6250) and total lysate assayed for transcript count as 
per manufacturers instructions. Total RNA was purified from organoids using the RNeasy 
Mini Kit (Qiagen) with 100 ng used for the assay.
mRNA analysis via NanoString.
Transcript abundance was compared using NanoString Elements platform. A custom gene 
set was created containing intestinal stem cell and differentiation genes including 5 
housekeeping genes (ActB, B2m, Cltc, GusB, Rpl19, Tbp, and Ywhaz). nSolver analysis 
software was used for data analysis with raw counts normalized to positive control probes 
and housekeeping genes. Only samples passing quality control were used for normalization 
and analysis. Data was visualized with Java Treeview and graphed using Prism 7 
(GraphPad). Source data for the generation of heat maps in the manuscript are provided in 
Supplemental Tables 1, 2, 3, and 4. Sequences for probe design and source data for the 
generation of heat maps has been uploaded as Supplemental Table 6.
Immunoblot analysis.
Biological replicate organoids from independent single cell isolations were harvested, 
washed in cold PBS and snap frozen. Pellets were resuspended in tissue lysis buffer 
containing protease and phosphatase inhibitors as previously described 13. Samples were 
disrupted by sonication, cleared by centrifugation at 10000g for 5 minutes, and protein 
concentration determined by BCA assay (Thermo Scientific) and diluted to allow for loading 
equal volumes. For histone acetylation assays organoids were collected and nuclei purified 
using the NE-PER Nuclear and Cytoplasmic Extraction Kit (ThermoFisher Catalog #78835) 
and following all instructions. Samples were resolved by SDS-PAGE, and analyzed by 
immunoblotting for organoid experiments and Tris-Tricine Gel for Drosophila experiments. 
Primary antibodies were obtained from Abcam or Cell Signaling Technology: Supplemental 
Table 5. Corresponding secondary antibodies (Rabbit:680 and Mouse:800 channel) were 
visualized using the Odyssey scanner (Li-Cor).
Schell et al. Page 14
Nat Cell Biol. Author manuscript; available in PMC 2018 September 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Steady state metabolomics.
For steady state metabolite accumulation control and knockout organoids were passaged to 
single cells and replated in basal media without drug (wENR). These organoids were grown 
for 8 days with media changes every 2–3 days and approximately 12 hours prior to harvest 
media was refreshed. For harvest organoids in matrigel were mechanically disrupted and 
dissolved using ice cold 0.9% sodium chloride, spun to 5000g for 30 seconds, supernatant 
aspirated and samples snap froze with liquid nitrogen. Metabolites were extracted as 
previously described 14. Briefly 450 uL of cold 90% methanol solution with internal 
standards (1 μg of d4-succinic acid) was added to each sample, vortexed briefly and 
sonicated for 3 minutes. This was kept at −20 degrees C for 1 hour, centrifuged at 20,000g 
for 5 minutes at 4 degrees C, and the supernatant transferred to a new tube, and sample was 
dried in a speed-vac. All GC-MS analysis was performed with a Waters GCT Premier mass 
spectrometer fitted with an Agilent 6890 gas chromatograph and a Gerstel MPS2 
autosampler. Dried samples were suspended in 40 μL of a 40 mg/mL O-methoxylamine 
hydrochloride (MOX) in pyridine and incubated for one hour at 30°C. Metabolites were 
identified and their peak area was recorded using QuanLynx. This data was transferred to an 
Excel spread sheet (Microsoft, Redmond WA). Metabolite identity was established using a 
combination of an in house metabolite library developed using pure purchased standards and 
the commercially available NIST library.
Flux metabolic labeling and Cell Lines.
Organoids were passaged and grown as above. Multiple (~30) 5 uL organoid matrigel spots 
were plated into wells of a 6 well plate, overlaid with media, and allowed to establish for 
approximately 1 week. 16 hours before beginning flux labeling, media was changed to 
minimal media (wENR as above) with and without UK-5099 (10 uM). At time 0 sample was 
taken for reference and media was removed, organoid plates washed gently with warm PBS 
and changed to flux media consisting of SILAC Advanced DMEM/F-12 (ThermoFisher 
#A2494301) with 10 mM U-13C6-Glucose (CLM-1396–10), growth factors and 
supplements as above but lacking glutamine, unlabeled glucose, or amino acids. Flux 
labeling of cell lines was carried out as above in DMEM lacking any carbon source 
(Invitrogen 11966025) supplemented with 10 mM U-13C6-Glucose (CLM-1396–10), 
Glutamax (Invitrogen #35050061), and 10% Fetal Calf Serum. For drug treatment 10 uM 
UK-5099 and 1 mM Valproic acid were added to above media. C2C12 cells were purchased 
from ATCC (CRL-1772) and tMEFs were a gift from Dean Tantin. No cell lines used in this 
study were found in the database of commonly misidentified cell lines that is maintained by 
ICLAC and NCBI Biosample. The cell lines were not authenticated and were not tested for 
mycoplasma contamination.
Electron microscopy.
Tissue was saved for electron microscopy by cutting approximately 1mm donuts and fixed 
overnight at 4 degree C in fresh 2.5% glutaraldehyde (Electron Microscopy Sciences 
#16320) diluted in PBS. The next day tissue was washed 3 times in Cacodylate buffer. 
Secondary fixation was carried out in 2% osmium tetroxide at room temperature for 1 hour 
followed by 2 washes with cacodylate buffer followed by 1 wash with water. Staining used 
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saturated uranyl acetate for 1 hour at room temperature, washed 3 times with water, and 
dehydrated with a graded ethanol series (30%, 50%, 70%, 95% × 2, 100% × 3, and finally 
absolute acetone). Infiltration with Epon epoxy resin (30% for 5 hours, 70% overnight, 
100% for 8 hours with 3 changes, and embedded with 100% fresh resin. Polymerization in 
fresh resin was carried out at 60 degrees C for 48 hours followed by ultracutting (Leica UC 
6ultratome) at 70 nm. Images were collected using a JEM-1400 Plus Transmission Electron 
Microscope (JEOL).
Seahorse.
Control and MPC1 knockout organoids for oxygen consumption studies were passaged by 
mechanical disruption rather than complete dissociation to single cells. Organoid fragments 
were spotted into a 6 well dish with multiple <10uL spots per well and overlaid with 2 mL 
of organoid growth media. Two days following plating at the first media change vehicle of 
UK5099 was added. For seahorse analysis organoids were extracted from Matrigel with 
gentle pipetting to minimize disaggregation. An XF96 well plate was coated with a 1:10 
dilution of matrigel in PBS and allowed to sit at RT for 1 hour. Organoids were evenly 
seeded in each well with the respective media (wENR CV +/− UK5099). The following day 
organoids were run on a XF96e Analyzer for a Mito Stress Test in standard assay media 
(DMEM, 25mM Glucose, 2mM pyruvate, 2mM Glutamine, pH 7.4) using manufacturers 
protocol and standard drug concentrations (Oligomycin 2uM, FCCP 2uM, Rotenone 0.5uM, 
and Antimycin A 0.5uM).
For Fatty Acid Oxidation: Substrate limited media was prepared as adapted from the 
stem cell recipe (all concentrations were kept the same except B27 supplement was 66.6uL, 
D-Glucose 0.5mM, 1mM Glutamine and Carnitine 0.5mM per 5mL of 4X media). The 
following drugs were added to substrate-limited media: 3uM CHIR99021, 1mM Valproic 
Acid, +/− 10uM UK5099. Media was changed and the organoids were maintained for 6 hrs 
in substrate-limited conditions. FAO Assay running buffer was standard 1X KHB (111mM 
NaCl, 4.7mM KCl, 1.25mM CaCl2, 2.0mM MgSO4, 1.2mM Na2HPO4) + 2.5mM D-
Glucose, 0.5mM L-Carnitine, and 5mM HEPES Buffer (pH 7.4). The following drugs were 
added to 1X KHB: 3uM CHIR99021, 1mM Valproic Acid, +/− 10uM UK5099. Following 
media change into 1X KHB, the plate was maintained at 37°C in a non- CO2 incubator and 
experimental conditions and controls were added 30min (40uM final Etomoxir, R&D 
Systems cat #: 4539) and 45min (BSA or Palmitate, Agilent cat #: 102720–100) following 
the media change added. Following the addition of the BSA or Palmitate substrates, the 
assay was run in the XF96e Analyzer for the Mito Stress Test. Assay protocol was adapted 
as follows (3 measurements per phase, acute injection followed by 3 min mixing, 3 min 
waiting, 3 min measuring) with the final concentrations of drugs as follow (Oligomycin 
2uM, FCCP 2uM, Rotenone 0.5uM, and Antimycin A 0.5uM). Normalization to cellular 
protein was quantified by Pierce BCA assay (Fisher Scientific cat #: 23227) and read on a 
photometric plate reader (Varioskan Flash). Results were analyzed in WAVE software and 
processed through the XF Mito Stress Test Report and Glycolysis Stress Test Generators.
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ENCODE ChIP-Seq for MPC1 Promoter.
This track shows ChIP-seq data from the Myers Lab at the Hudson Alpha Institute for 
Biotechnology and by the labs of Michael Snyder, Mark Gerstein, Sherman Weissman at 
Yale University, Peggy Farnham at the University of Southern California, Kevin Struhl at 
Harvard, Kevin White at the University of Chicago, and Vishy Iyer at the University of 
Texas, Austin. These data were processed into uniform peak calls by the ENCODE Analysis 
Working Group pipeline developed by Anshul Kundaje. The clustering of the uniform peaks 
was performed by UCSC (https://genome.ucsc.edu/cgi-bin/hgGateway). The Factorbook 
motif identifications and localizations (and valuable assistance with interpretation) were 
provided by Jie Wang, Bong Hyun Kim and Jiali Zhuang of the Zlab (Weng Lab) at UMass 
Medical School.
Statistics and Reproducibility.
No pre-specified effect size was calculated, no statistical method was used to predetermine 
sample size. For comparisons of multiple groups an ordinary one-way ANOVA with Dunnett 
or Holm-Sidak correction for multiple comparisons (Figure 1a groups compared to low, 1c 
groups compared to EN, 4f groups compared to wENR). Statistical tests were appropriate 
for comparisons being made, for all t-tests and ANOVA data meet assumptions of the tests, 
assessment of variation was carried out but not included. For mouse studies, an n of 10 was 
chosen for control (equal Lgr5-EGFP heterozygous × Mpc1 wt/wt and Lgr5-EGFP wild-
type × Mpc1 fl/fl) and knockout (Lgr5-EGFP heterozygous × Mpc1 fl/fl) comprised of both 
males and females. No statistical method was used to predetermine sample size. 
Experiments were not randomized. Investigators were not blinded to allocation during 
experiments and outcome assessment. Reproducibility: Fig. 2a: representative of two 
experiments; Fig. 2b: representative of two experiments; Fig. 2c representative of three 
experiments (pooled); Fig. 2d representative of three experiments; Fig. 2e representative of 
two experiments; Fig. 2f representative of two experiments; Fig. 2g representative of three 
experiments; Fig. 4a: representative of two experiments; Fig. 4b: representative of two 
experiments; Fig. 4c: representative of two experiments; Fig. 4d: representative of two 
experiments; Fig. 4g: representative of two experiments; Fig. 5d: representative of two 
experiments; Fig. 6a: representative of two experiments; Fig. 6b: representative of two 
experiments; Fig. 6c: representative of two experiments; Fig. 6d: representative of two 
experiments; Fig. 6e: four individual patients, n = 6 replicates, averaged and pooled; Fig. 6g: 
representative of two experiments; Fig. 6h: representative of two experiments; Fig. 6k: two 
independent infections, data pooled; Fig. S2a: representative of three experiments; Fig. S4b: 
representative of three experiments; Fig. S6a: representative of two experiments; Fig. S6b: 
two independent infections, data pooled (as in Fig. 6k).
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Figure 1: MPC expression is low in intestinal stem cells and increases upon differentiation.
a, The indicated transcripts were quantified in Lgr5-EGFP cells sorted for low, mid, and 
high EGFP intensity (n = 13, low and mid, n = 12 high). b, Heat map of mRNA content 
from the Lgr5-EGFP populations in (a). c, The indicated transcripts were quantified from 
organoids transferred to differentiation conditions (EN: EGF and Noggin) compared to stem-
maintaining conditions containing RSPO1 (ENR) or RSPO1 and Wnt3A (ENR + Wnt) (n = 
3 per treatment). d, Heat map of mRNA content from organoids in (c). e, Antibody stain of 
MPC1 and VDAC on crypts of proximal small intestine in mouse (top) and human (bottom). 
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f, Immunofluorescence images of mouse proximal small intestine staining for MPC1 (red) 
and EGFP for Lgr5 intestinal stem cells (green). g, Electron micrographs of enterocytes 
(left) and crypt stem cells and surrounding paneth cells (right) at low (top) and high (bottom) 
magnification. Yellow arrows indicate mitochondria. h, Isolated live crypts imaged for Lgr5-
EGFP and co-stained with MitoTracker Red CMXRos. Data are mean ± s.e.m. *P < 0.05, 
**P < 0.01, ***P < 0.001. Scale bars, 50 μm (e, human, h) and 20 μm (e (mouse), f). P 
values for 1a and 1c were calculated by One-way ANOVA with correction for multiple 
comparisons.
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Figure 2: Drosophila MPC regulates intestinal stem cell proliferation.
a, Intestines from controls and dMPC1 mutants stained with phalliodin (red) and DAPI 
(blue), (n = 10 control, n = 7 knockout). b, MARCM dMPC1 mutant clones marked by GFP 
along with quantification of clone size, (n = 13 clones from control, n = 12 clones from 
knockout, 15 animals assessed for each group. c, MARCM dMPC1 mutant clones with 
Notch RNAi marked by GFP along with quantification, (n = 31 from control, n = 38 from 
knockout). d, Dl-GAL4 used to target RNAi as indicated, (Control n = 8, dMPC RNAi n = 8, 
dMPC2 RNAi n = 8, PDH E1 n = 7, PDH E2 n = 7 experimental replicates). Increased 
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proliferation as detected by staining for phosphorylated histone H3 (pHH3), (PHH3 + cells 
counted from control n= 8, dMPC1 RNAi n= 8, PDH E1 n= 7). e, Dl-GAL4 used to target 
RNAi as indicated or MPC overexpression (o/e) under infected conditions, (Control n = 5 
(no infection) Control with infection n = 10, MPC O/E n = 10, LDH RNAi n = 10 MPC 
RNAi n = 10 PDH RNAi n = 10). f, esg-GAL4 was used to target RNAi as indicated or MPC 
overexpression (o/e) under uninfected basal conditions, 23 days old at 29°C, (Control n = 
10, MPC O/E n = 10, LDH RNAi n = 10 MPC RNAi n = 10). g, Intestine size is unaffected 
in animals overexpressing the MPC under basal conditions in aged flies (left two panels) and 
reduced in infected animals (right two panels) (n = 10 for Control and MPC O/E). Data are 
mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. All p values were calculated using 
Student’s t-test.
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Figure 3: MPC deletion in the Lgr5-EGFP compartment increases intestinal stem cells 
maintenance and proliferation.
a, Images of H&E, MPC1, CK20, ki67, Alcian Blue, VDAC, Lrig1, and BrdU staining in 
control and Mpc1Lgr5-KO proximal small intestine. b, Representative images and 
quantification of BrdU stained percent of crypt nuclei in control and Mpc1Lgr5-KO animals 
(n = 9 control, n=10 knockout) c, Representative images and quantification of ki67 positive 
nuclei percent of total in crypts of control and Mpc1Lgr5-KO animals (n = 9 control, n=10 
knockout) d, Representative images of Olfm4 in situ hybridization of control and 
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Mpc1Lgr5-KO small intestine with quantification of positive cells per crypt (right) (n = 9 
control and knockout) e, Images of GFP stained cells in control and Mpc1Lgr5-KO animals 
with quantification of GFP positive cells per crypt (n = 9 control and knockout) f, Percent 
area of proximal small intestine without MPC1 by IHC in animals 8, 30, and 160 days post-
tamoxifen treatment (n = 5 for 8 and 30 day, n = 4 for 160 day). Data are mean ± s.e.m. *P < 
0.05, **P < 0.01, ***P < 0.001. Scale bars, 100 μm (a) and 20 μm (b, c, d, and e). All p 
values were calculated using Student’s t-test.
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Figure 4: In vitro loss of the MPC increases stem cell function and organoid formation.
a, Quantitation of organoid formation from intestinal crypts isolated from control and Mpc1 
KO mice treated with tamoxifen (n = 3 control, n=4 knockout animals with 10 separate 
organoid cultures from each animal). b, Quantitation of organoid formation from single 
Lgr5-EGFP+ cells from Mpc1fl/fl intestines after in vitro vehicle (control) or tamoxifen (KO) 
treatment (n = 20 experimental replicates). c, Images of mature organoids grown from cells 
in (b). Blue arrows denote Lgr5-EGFP+ crypt domains and yellow asterisks indicate 
autofluorescent lumens. d, Flow cytometry for cells in (b) showing percent GFP positive (n 
= 5 control, = 6 knockout). e, Secondary organoid formation from single cells passaged from 
(b) as single live cells (n = 20 experimental replicates). f, Fraction of Lgr5-EGFP expressing 
secondary organoids in control and Mpc1 KO cultures (n = 20 experimental replicates). g, 
Images of control and Mpc1 KO organoids upon withdrawal of stem cell maintaining drugs 
CHIR99021 and valproic acid (representative of 2 experiments). Blue arrows denote Lgr5-
EGFP+ cells and yellow asterisks indicate autofluorescent lumens. Data are mean ± s.e.m. 
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*P < 0.05, **P < 0.01, ***P < 0.001. Scale bars, 100 μm (c, g). All p values were calculated 
using Student’s t-test.
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Figure 5: In vitro loss of the MPC alters protein expression and metabolism.
a, Immunoblot of replicate control and Mpc1Lgr5-KO organoid cultures with villi and crypt 
extract as negative and positive controls respectively. b, Immunoblot on isolated nuclei from 
control and Mpc1Lgr5-KO organoids for acetyl Histone 3 marks. c,. Steady state abundance of 
citrate and pyruvate in control and Mpc1Lgr5-KO organoids (n = 6 experimental replicates). 
d, Flux metabolic labeling of citrate (M+0 on top, M+2 on bottom) at times following 
U-13C-glucose addition in control and Mpc1Lgr5-KO organoids with and without UK-5099 
treatment (n = 1 for 0 hour per condition and n= 3 for each additional time point). e, Oxygen 
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consumption of control and Mpc1 KO organoids with and without UK-5099 utilizing 
glucose for respiration (n = 8 experimental replicates). f, Etomoxir sensitive oxygen 
consumption of control and Mpc1Lgr5-KO organoids with and without UK-5099 treatment 
utilizing palmitate for respiration (n = 3 experimental replicates). Data are mean ± s.e.m. *P 
< 0.05, **P < 0.01, ***P < 0.001. All p values were calculated using Student’s t-test. 
Unprocessed western blots are provided in Supplementary Figure 7.
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Figure 6: In vitro inhibition of MPC activity increases organoid formation.
a, Images of organoids from crypts with and without UK-5099. Blue arrow points to Lgr5-
EGFP+ crypt domain and purple asterisks indicate autofluorescent lumens. b, Quantification 
of crypt domains per organoid with and without UK-5099 (n = 6 experimental replicates). c, 
Quantification of organoid formation from crypts from proximal small intestine with and 
without UK-5099 (n = 16 wENR, n= 14 UK-5099 experimental replicates). d, Flow 
cytometry for cells in (c) showing percent GFP positive (n = 3 replicates per condition). e, 
Human ascending colon crypts treated with wENR basal media (set to 1) or media 
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containing UK-5099 or CHIR+VAL (n = 5 patients with 6–8 individual cultures per patient 
sample). f, Representative images and quantification of crypt domains in organoids 
maintained with and without UK-5099 for 12 months (wENR n = 46 organoids from 2 
separate wells, UK-5099 n = 26 organoids from 2 separate wells). g, Images of organoids 
treated with IWP-2 and DAPT to promote differentiation with and without UK-5099. Blue 
arrows point to crypt domains and yellow asterisks indicate autofluorescent lumens. h, 
Organoid formation from crypts treated with the indicated single, double, and triple drug 
combinations (CHIR = CHIR99021 and VAL = valproic acid) (n = 10 experimental 
replicates, p values are for each treatment compared to wENR). i, Transcript abundance in 
organoids showing the ratio of UK5099 treated to control (n = 3 experimental replicates, p 
values calculated for each transcript compared to wENR). j, Heat map for additional 
transcripts from (i). k, Probability of cells infected with virus containing empty vector or 
both MPC1-iRFP and MPC2-mCherry also being GFP positive (n = 4 independent 
organoids with at least 15 infected cells counted). Data are mean ± s.e.m. *P < 0.05, **P < 
0.01, ***P < 0.001. Scale bars, 50 μm (a,) and 100 μm (f, g). P values for 6h were calculated 
by One-way ANOVA with correction for multiple comparisons. All other p values were 
calculated using Student’s t-test.
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